Profilo
Chulho Park is the founder of Oncotelic, Inc. (founded in 2015) where he holds the title of Chief Technology Officer.
He was also the founder of Mabprex, Inc. (founded in 2010) where he held the title of Chief Executive Officer until 2018.
Dr. Park's former jobs include being the Chief Technology Officer at Oncotelic Therapeutics, Inc. from 2019 to 2021 and being the President-Pharmaceutical Development at IgDraSol, Inc. in 2013.
Posizioni attive di Chulho Park
| Società | Posizione | Inizio |
|---|---|---|
Oncotelic, Inc.
 Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Founder | 01/01/2015 |
Precedenti posizioni note di Chulho Park
| Società | Posizione | Fine |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2021 |
| Mabprex, Inc. | Chief Executive Officer | 01/01/2018 |
IgDraSol, Inc.
 IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a private company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Corporate Officer/Principal | 01/09/2013 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
IgDraSol, Inc.
IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a private company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Health Technology |
Oncotelic, Inc.
Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Health Technology |
| Mabprex, Inc. |
- Borsa valori
- Insiders
- Chulho Park
